New Report Available: South Africa Pharmaceuticals & Healthcare Report Q3 2016

South Africa boasts the largest pharmaceutical market in Africa, and already has a well-established manufacturing industry supported by foreign investment. An improving regulatory environment, promising economic growth and high per capita spending will all contribute to South Africa's increasingly attractive operating environment. M ore companies will express an interest in South Africa's pharmaceutical market in the coming years as part of a strategy to increase both the scale of their manufacturing footprint and also their product portfolio in emerging S ub-Saharan markets.

Headline Expenditure Projections

Pharmaceuticals: ZAR43.41bn (USD3.40bn) in 2015 to ZAR47.48bn (USD3.04bn) in 2016; +9.4% in local currency terms and -10.7% in US dollar terms. Forecast revised upwards from last quarter.

Full Report Details at
- http://www.fastmr.com/prod/1197578_south_africa_pharmaceuticals.aspx?afid=301

Healthcare: ZAR359.7bn (USD28.2bn) in 2015 to ZAR387.3bn (USD24.8bn) in 2016; +7.7% in local currency terms and -12.1% in US dollar terms. Forecast revised upwards from last quarter.

Risk/Reward Index

South Africa has strong longer-term commercial potential because of its sizeable population and economic development. However, the impact of currency depreciation and a worsening economic outlook have hurt its short-term growth prospects. In Q316, South Africa's dropped from 10th to 11th position in the matrix compared to the previous quarter, with a score of 46.3 out of 100.

Latest Updates

Navamedic has expanded its Nordic portfolio of products from South Africa-based Aspen Pharmacare. From January 1, four new products have been added to the portfolio and are expected to represent sales of around NOK30mn (USD3.4mn). The four products are Eltroxin (thyroxine), Lanoxin (digoxin), Imuran (azathioprine) and Zyloric (allopurinol). Navamedic has distributed Aspen products in the Nordic and Benelux markets since 2010 and the South African pharma is currently Navamedic's largest supplier. Navamedic commented that the expansion of the agreement with Aspen is in line with its aims to grow sales and increase margins in its Nordic Partnership Business, through which it distributes and licenses contracts for pharmaceuticals and other healthcare products.

At the annual Union World Conference on Lung Health in Cape Town in December 2016, researchers introduced a new treatment for tuberculosis (TB). Many children with TB never complete their treatment as they reject their cut or crashed-up portions of adult-sized pills. The new strawberry- and raspberry-flavoured tablets dissolve in water and come in specific kid-sized doses.

BMI Economic View

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Egypt Pharmaceuticals & Healthcare Report Q3 2016
- Ghana Pharmaceuticals & Healthcare Report Q3 2016
- Kenya Pharmaceuticals & Healthcare Report Q3 2016
- Qatar Pharmaceuticals & Healthcare Report Q3 2016
- Bahrain Pharmaceuticals & Healthcare Report Q3 2016